Last reviewed · How we verify
NCT05398224
R-MTX-zanbrutinib in Secondary CNS Lymphoma
Phase 2 trial testing Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab in Secondary Central Nervous System Lymphoma in 45 participants. Status unknown.
26 February 2024
Quick facts
| Lead sponsor | Peking University |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 26 February 2021 |
| Primary completion | 26 February 2024 |
| Estimated completion | 26 May 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab — full drug profile →
Conditions studied
- Secondary Central Nervous System Lymphoma — all drugs for Secondary Central Nervous System Lymphoma →
Sponsor
Peking University
Who can join
Adults 18 to 75, any sex, with Secondary Central Nervous System Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Secondary central nervous system lymphoma (SCNSL) occurred in about 5% of patients with diffuse large B-cell lymphoma (DLBCL). The prognosis of SCNSL is very poor. A number of retrospective studies have shown that the median overall survival (mOS) since the diagnosis of CNSL is only 2.5-3.5 months, and the 2-year OS rate is only 20%. At present, there is no consensus on the treatment of SCNSL, and new therapeutic strategies are urgently needed. Zanubrutinib is a new second-generation BTK inhibitor, which has showed good efficacy and safety in a variety of B-NHL. Zanubrutinib has showed good blood-brain barrier permeability in preclinical studies. This study attempts to evaluate the efficacy and safety of zanubrutinib combined with rituximab and high-dose methotrexate in the treatment of SCNSL in patients with DLBCL.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05398224
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Secondary Central Nervous System Lymphoma
Currently open trials in the same condition.
- NCT06922604 — Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma · Phase 1 · recruiting
- NCT05256641 — Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma · Phase 1, PHASE2 · recruiting
- NCT05351593 — Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma · Phase 1, PHASE2 · recruiting
- NCT05011045 — Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies · recruiting
- NCT03964090 — Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Se · Phase 2 · active not recruiting
Other Peking University trials
Trials by the same sponsor.
- NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
- NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
- NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
- NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
- NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05398224 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University
- Last refreshed: 31 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05398224.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing